Clinical Trials Logo

Filter by:
NCT ID: NCT00495885 Completed - Clinical trials for Sleep Initiation and Maintenance Disorders

Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus

SAMS12
Start date: June 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess efficacy and safety of volinanserin in the population of patients complaining of sleep maintenance insomnia. The objective of the substudy is to assess glycemic control in the subgroup of patients with type II diabetes mellitus.

NCT ID: NCT00495781 Completed - Clinical trials for Functional Iron Deficiency

Out Come Study To Define Laboratory Parameters That Are Best Suited to Diagnose Functional Iron Deficiency

SFIDS
Start date: October 2004
Phase: N/A
Study type: Interventional

The purpose of the study is to define laboratory parameters which are best suited to diagnose functional iron deficiency. Functional iron deficiency is a condition where - due to the lack of iron bioavailability - the patient suffers from symptoms such as fatigue and weakness, or his/her capacity to produce red blood cells is reduced.

NCT ID: NCT00494390 Completed - Cataract Clinical Trials

Evaluation Study for a Non-Contact Biometer

Start date: July 2007
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether a new non-contact biometer, is as accurate as the the available gold-standard.

NCT ID: NCT00494325 Completed - Clinical trials for Age Related Maculopathy

The Role of Macular Pigment in Patients With Age-related Macular Degeneration

Start date: October 2005
Phase:
Study type: Observational

In the industrialised world age-related macular degeneration (ARMD) is the leading cause for legal blindness beyond the age of 50 years. Recent studies indicate that the amount and status of the macular pigment (MP) may play a central role in the development and progression of the disease. It has been demonstrated that the MP density can be increased by dietary supplementation. First results of MP density measurements with a modified confocal laser scanning ophthalmoscope show that this method allows to quantify the MP in a clinical setting. The aim of this study is to assess the peak MP density as well as the MP distribution in relation to the risk for ARMD. We will establish reference values for MP density distribution in a normal population and compare these to values obtained from patients with age related maculopathy in a cross-sectional study. For all MP density measurements we will use a modified scanning laser ophthalmoscope and dietary intake of macular pigment will be assessed using a Food Frequency Questionnaire. Clinical examinations will include ETDRS visual acuity, binocular ophthalmoscopy, colour fundus photography and autofluorescence imaging. The results of our study will help assess the relationship of macular pigment density and distribution with ARMD. Additionally, we will be able to identify patients with low MP density, and probably improve the early diagnosis of patients at high risk for developing ARMD. This will be the basis for dietary supplementation of lutein and/or zeaxanthin in patients with high risk for ARMD due to low macular pigment values.

NCT ID: NCT00492986 Completed - Clinical trials for Carcinoma, Renal Cell

An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma

Start date: October 2005
Phase: Phase 3
Study type: Interventional

Purpose of the study: The purpose of this study is to make sorafenib available for patients with advanced Renal Cell Carcinoma, who have failed prior systemic therapy for advanced disease (i.e. requiring second line treatment), and who do not have access to or are not eligible for other clinical trials with sorafenib and who may benefit from treatment with sorafenib. Patients will be treated orally with 400 mg bid sorafenib on a continuous basis and as a single agent. Patients may continue treatment until Disease Progression, intolerable toxicity, the patients chooses to withdraw consent or the patient is unlikely to benefit any further from treatment. Overall, participation in the study will help determine the following: - Find out if patients receiving Sorafenib will live longer - Find out if Sorafenib helps to slow the worsening of kidney cancer - Find out if Sorafenib has an effect on the tumours

NCT ID: NCT00492908 Completed - Clinical trials for Coronary Heart Disease

Randomized Trial Comparing Titan Stent With Zotarolimus-Eluting Stent

Start date: June 2007
Phase: Phase 4
Study type: Interventional

A Randomized Comparison of a Titanium-Nitride-Oxide Coated Stent (Helistent Titan2, Hexacath) With a Zotarolimus-Eluting Stent (EndeavorTm, Medtronic) for Percutaneous Coronary Intervention

NCT ID: NCT00492895 Completed - Skin Cancer Clinical Trials

Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients

Start date: June 2007
Phase: Phase 4
Study type: Interventional

Photosensitivity of the skin to UVA and UVB will be determined

NCT ID: NCT00492804 Completed - Inguinal Hernia Clinical Trials

Elective Neurectomy During Inguinal Hernia Repair

Start date: July 2005
Phase: Phase 2
Study type: Interventional

Chronic inguinal neuralgia is one of the most important complications following inguinal hernia repair. It may even outweigh the benefit of the operation. Intraoperative neurectomy has been investigated to reduce the incidence of chronic pain. This study evaluates the effects of elective division of the ilioinguinal, iliohypogastric and genital branch of the genitofemoral nerves on pain and postoperative sensory symptoms after Lichtenstein hernia repair.

NCT ID: NCT00492739 Recruiting - Immunosuppression Clinical Trials

Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients

VZVinOLTx
Start date: June 2007
Phase: Phase 2/Phase 3
Study type: Interventional

Varicella is a vaccine-preventable disease, which can be severe in immunosuppressed children. Currently, the (live) vaccine is not recommended in pediatric orthotopic liver transplant recipients. Furthermore, protection due to naturally acquired immunity to VZV or post-immunization isn't well described in this population.The questions asked are: - What is the influence of the immunosuppression required after orthotopic liver transplantation (OLT) on the maintenance of VZV-specific immunity elicited by wild-type varicella infection before OLT transplantation? - What is the influence of the immunosuppression required after OLT on VZV-specific immunity elicited by varicella immunization before OLT transplantation? - What is the influence of the residual immunosuppression at ≥ 12 months after OLT transplantation on the induction of VZV-specific B and T cell responses elicited by VZV vaccination after OLT transplantation? - What is the influence of the residual immunosuppression at ≥ 12 months after OLT transplantation on the persistence / waning of B and T cell responses elicited by VZV vaccination?

NCT ID: NCT00492713 Completed - Healthy Clinical Trials

Polyphenol Bioavailability From Chocolate

Start date: June 2007
Phase: N/A
Study type: Interventional

Dark chocolate is one of the richest sources of polyphenols though it has been hypothesised that the bioavailability of epicatechin from milk chocolate was reduced compared to dark. The primary outcome measure is to compare plasma polyphenol levels after consumption of 3 chocolates (2 milk, 1 dark) while the secondary outcome measures are to characterise the time course of polyphenols in the blood and to investigate individual variation in Tmax and Cmax for use in future studies.